Table 1

Baseline characteristics

Order-set used
n=263
Order-set not used
n=78
P value
Female, n (%)108 (41)27 (35)0.31
Caucasian race, n (%)204 (84)64 (86)0.55
Age, mean (SD)56.0 (10.5)58.9 (11.3)0.05
MELD, mean (SD)20.7 (8.5)21.0 (7.2)0.79
MELD-Na, mean (SD)19.7 (10.2)21.3 (8.4%)0.20
Aetiology of liver disease0.22
 Alcohol, n (%)113 (45)27 (35)
 Hepatitis C, n (%)28 (11)14 (18)
 Alcohol and hepatitis C, n (%)28 (11)7 (9)
 Other, n (%)81 (32)29 (38)
Comorbid conditions
 CKD, n (%)60 (23)12 (15)0.16
 ESRD, n (%)14 (5)4 (5)1.00
 HIV, n (%)1 (0.4)1 (1)0.41
 Diabetes, n (%)104 (40)27 (35)0.43
 COPD, n (%)20 (8)8 (10)0.45
 Coronary artery disease, n (%)21 (8)7 (9)0.78
No. of hospital encounters, n736244
Rifaximin use, n (%)712 (97)203 (83)<0.001
Precipitant of HE0.13
 Medication non-adherence, n (%)247 (34)80 (33)
 Unknown precipitant, n (%)128 (17)64 (23)
 GI bleed, n (%)33 (4)13 (5)
 Urinary tract infection, n (%)76 (10)13 (5)
 Spontaneous bacterial peritonitis, n (%)44 (6)13 (5)
 Other, n (%)208 (28)70 (29)
  • CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; GI, Gastrointestinal; HE, hepatic encephalopathy; MELD, model of end-stage liver disease.